Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Asenapine

FDA-approved product (system, transdermal), marketed as Secuado, Asenapine Maleate, Saphris.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Asenapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Asenapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Asenapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)

    NCT01098110 · start 2010-05-25

    Registered record
    Registry ID
    NCT01098110
    Conditions
    Schizophrenia
    Interventions
    Asenapine 5 mg; Asenapine 10 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05-25
    Completion
    2014-04-14
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAsenapine 5 mg; Asenapine 10 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

    NCT01142596 · start 2010-05-25

    Registered record
    Registry ID
    NCT01142596
    Conditions
    Schizophrenia
    Interventions
    Asenapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05-25
    Completion
    2015-04-22
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAsenapine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

    NCT00806234 · start 2009-01

    Registered record
    Registry ID
    NCT00806234
    Conditions
    Psychotic Disorders
    Interventions
    Aripiprazole or Perphenazine; Metformin; Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2014-03
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders
    InterventionAripiprazole or Perphenazine; Metformin; Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
    PhasePhase 4
    Registry statusCompleted

  • 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

    NCT00265343 · start 2005-12

    Registered record
    Registry ID
    NCT00265343
    Conditions
    Schizophrenia
    Interventions
    asenapine; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-01
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionasenapine; olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)

    NCT00156065 · start 2005-09

    Registered record
    Registry ID
    NCT00156065
    Conditions
    Schizophrenia
    Interventions
    Haloperidol; Asenapine; Asenapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-10
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionHaloperidol; Asenapine; Asenapine
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

    NCT00156104 · start 2005-07-01

    Registered record
    Registry ID
    NCT00156104
    Conditions
    Schizophrenia
    Interventions
    Asenapine; Asenapine; Haloperidol; Placebo arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07-01
    Completion
    2006-09-16
    Enrolment
    460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAsenapine; Asenapine; Haloperidol; Placebo arm
    PhasePhase 3
    Registry statusCompleted

  • 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

    NCT00159783 · start 2005-07

    Registered record
    Registry ID
    NCT00159783
    Conditions
    Bipolar Disorder
    Interventions
    asenapine; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2007-04
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventionasenapine; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

    NCT00174265 · start 2005-07

    Registered record
    Registry ID
    NCT00174265
    Conditions
    Schizophrenia
    Interventions
    asenapine; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2009-05
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionasenapine; olanzapine
    PhasePhase 3
    Registry statusCompleted

  • 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

    NCT00145470 · start 2005-06-02

    Registered record
    Registry ID
    NCT00145470
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-06-02
    Completion
    2007-03-22
    Enrolment
    326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

    NCT00156117 · start 2005-05-12

    Registered record
    Registry ID
    NCT00156117
    Conditions
    Schizophrenia
    Interventions
    asenapine; Placebo; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05-12
    Completion
    2006-05-30
    Enrolment
    417

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionasenapine; Placebo; olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

    NCT00212836 · start 2005-04-21

    Registered record
    Registry ID
    NCT00212836
    Conditions
    Schizophrenia
    Interventions
    asenapine; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04-21
    Completion
    2007-08-02
    Enrolment
    481

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionasenapine; olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

    NCT00156091 · start 2005-04

    Registered record
    Registry ID
    NCT00156091
    Conditions
    Schizophrenia
    Interventions
    Olanzapine; Asenapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-06
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOlanzapine; Asenapine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

    NCT00151424 · start 2005-02-15

    Registered record
    Registry ID
    NCT00151424
    Conditions
    Schizophrenia
    Interventions
    asenapine; Placebo; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02-15
    Completion
    2006-02-06
    Enrolment
    277

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionasenapine; Placebo; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

    NCT00143182 · start 2005-01-07

    Registered record
    Registry ID
    NCT00143182
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01-07
    Completion
    2006-06-28
    Enrolment
    504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

    NCT00159796 · start 2004-12-14

    Registered record
    Registry ID
    NCT00159796
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12-14
    Completion
    2006-04-28
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Olanzapine; Placebo
    PhasePhase 3
    Registry statusCompleted